
    
      Patients with primary progressive MS or secondary progressive MS without relapses during the
      last 1 year will be suitable for the trial. In all 56 patients will be enrolled into the
      study.

      The primary outcome measure is the change from baseline to 24 weeks in a composite of maximum
      gait distance, 9-hole peg test, TRAIL making B comparing the placebo-treatment group with the
      EPO-treatment group.
    
  